GH1 and hepatocellular carcinoma: In the current study, we demonstrated for the first time that specific blockade of GH/GHR signaling pathway using pegvisomant, an FDA-approved drug, potentiates the effects of sorafenib and overcomes its resistance in nude mice xenograft tumors as well as in two HCC patients who developed resistance and progressed on sorafenib.